Published ahead of print on October 25, 2007, doi:10.1164/rccm.200708-1194OC
© 2008 American Thoracic Society doi: 10.1164/rccm.200708-1194OC
The Effect of Lung Volume Reduction Surgery on Chronic Obstructive Pulmonary Disease Exacerbations1 Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; 2 University of Washington, Seattle, Washington; 3 VA Puget Sound Health Care System, Seattle, Washington; 4 Fred Hutchinson Cancer Research Center, Seattle, Washington; 5 Cedars-Sinai Medical Center, Los Angeles, California; 6 University of Michigan, Ann Arbor, Michigan; 7 National Jewish Medical and Research Center, Denver, Colorado; 8 University of Pittsburgh, Pittsburgh, Pennsylvania; 9 Temple University, Philadelphia, Pennsylvania; 10 Cleveland Clinic Foundation, Cleveland, Ohio; and 11 Beth Israel Deaconess Medical Center, Boston, Massachusetts Correspondence and requests for reprints should be addressed to George R. Washko, M.D., Pulmonary and Critical Care Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. E-mail: gwashko{at}partners.org Rationale: Lung volume reduction surgery (LVRS) has been demonstrated to provide a functional and mortality benefit to a select group of subjects with chronic obstructive pulmonary disease (COPD). The effect of LVRS on COPD exacerbations has not been as extensively studied, and whether improvement in postoperative lung function alters the risk of disease exacerbations is not known. Objectives: To examine the effect, and mechanism of potential benefit, of LVRS on COPD exacerbations by comparing the medical and surgical cohorts of the National Emphysema Treatment Trial (NETT). Methods: A COPD exacerbation was defined using Centers for Medicare and Medicaid Services data and International Classification of Diseases, Ninth Revision, discharge diagnosis. Measurements and Main Results: There was no difference in exacerbation rate or time to first exacerbation between the medical and surgical cohorts during the year before study randomization (P = 0.58 and 0.85, respectively). Postrandomization, the surgical cohort experienced an approximate 30% reduction in exacerbation frequency (P = 0.0005). This effect was greatest in those subjects with the largest postoperative improvement in FEV1 (P = 0.04) when controlling for changes in other spirometric measures of lung function, lung capacities, and room air arterial blood gas tensions. Finally, LVRS increased the time to first exacerbation in both those subjects with and those without a prior history of exacerbations (P = 0.0002 and P < 0.0001, respectively). Conclusions: LVRS reduces the frequency of COPD exacerbations and increases the time to first exacerbation. One explanation for this benefit may be the postoperative improvement in lung function. Clinical trial registered with www.clinicaltrials.gov (NCT 00000606).
Key Words: COPD • LVRS • exacerbation
Related articles in AJRCCM:
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
